Cetuximab (PBS)

• Description:

  Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect[1].

• UNSPSC:

  12352203

• Target:

  EGFR; Radionuclide-Drug Conjugates (RDCs)

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.3

• Smiles:

  [Cetuximab(PBS)]

• Molecular Weight:

  (145.54 kDa)

• References & Citations:

  [1]Goldstein, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical cancer research: an official journal of the American Association for Cancer Research 1.11 (1995) : 1311-1318.|[2]Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.|[3]Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59 (8) :1935-40.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  -80°C

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported